Phase II trial of sorafenib in esophageal (E) and gastroesophageal junction (GEJ) cancer: Response and protracted stable disease observed in adenocarcinoma.
D. Ilson
Research Funding - Bayer; Bristol-Myers Squibb; Genentech; Sanofi
Y. Y. Janjigian
No relevant relationships to disclose
M. A. Shah
No relevant relationships to disclose
D. P. Kelsen
No relevant relationships to disclose
L. H. Tang
No relevant relationships to disclose
J. Campbell
No relevant relationships to disclose
L. Fuqua
No relevant relationships to disclose
M. Capanu
No relevant relationships to disclose